New directions in non-small cell lung cancer

R. J. Gralla

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with nonresectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalSeminars in oncology
Issue number4 SUPPL. 7
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'New directions in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this